Recruiting

Radiation therapy combined with targeted lung cancer medication

Plain-English translation of NCT05724004 on ClinicalTrials.gov ↗ · Source last updated October 2023 · Translation generated July 2026 · How we translate trials

This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.

What is this trial?

This trial is testing a two-part approach for people with advanced non-small cell lung cancer that has an ALK gene mutation. First, you would take alectinib, a targeted medication, for 2–3 months. Then, if your cancer responds well or stays stable, you would receive radiation therapy to all visible tumors while continuing to take the medication.

Doctors want to see if adding radiation therapy to this medication can help patients live longer without their cancer getting worse. Right now, the medication alone is the standard treatment, but combining it with radiation might be more effective.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced non-small cell lung cancer (stage III or IV) with an ALK gene mutation
your cancer has responded well to or remained stable after 2–3 months of treatment with alectinib
you have no more than 5 active tumor spots visible on a special imaging scan
all of your tumors can be treated with radiation therapy
your lungs and other organs are healthy enough to tolerate both the medication and radiation

You likely don't qualify if…

you have cancer that has spread to the protective lining around your brain or spinal cord
your cancer has progressed or gotten worse despite taking alectinib for 2–3 months
you have received other targeted drugs, chemotherapy, or immunotherapy for advanced cancer before
you have received radiation therapy for lung cancer or any other cancer in the last 3 years
you have a history of lung scarring or inflammation (interstitial lung disease or pulmonary fibrosis)

What participation looks like

You would start by taking alectinib as a tablet for 2–3 months to see how your cancer responds. Then, if your cancer is stable or improving, you would receive radiation therapy sessions targeted at all your tumors while continuing to take the medication. After radiation finishes, you would keep taking the medication until your cancer progresses or side effects become unacceptable. Throughout the trial, you would have regular visits with your medical team to monitor your response and any side effects.

AI-generated summary from trial data · Jul 21, 2026 · Not medical advice

Trial locations(1 site)

Sweden

Karolinska University Hospital, Stockholm